By Lauran Neergaard and Mike Stobbe

U.S. health authorities said Thursday that 16- and 17-year-olds should get a booster dose of Pfizer's COVID-19 vaccine once they're six months past their last shot.

The U.S. and many other nations already were urging adults to get booster shots to pump up immunity that can wane months after vaccination, calls that intensified with the discovery of the worrisome new omicron variant.

On Thursday, the Food and Drug Administration gave emergency authorization for 16- and 17-year-olds to get a third dose of the vaccine made by Pfizer and its partner BioNTech. And hours later, the Centers for Disease Control and Prevention lifted the last barrier — saying those teens should get their booster as soon as it's time.

CDC Director Rochelle Walensky told The Associated Press the boosters are important considering that protection against infection wanes over time and “we’re facing a variant that has the potential to require more immunity to be protected.”

“Vaccination and getting a booster when eligible, along with other preventive measures like masking and avoiding large crowds and poorly ventilated spaces, remain our most effective methods for fighting COVID-19,” Dr. Janet Woodcock, acting FDA commissioner, said in a statement.

The Pfizer vaccine is the only option in the U.S. for anyone younger than 18, either for initial vaccination or for use as a booster. It’s not yet clear if or when teens younger than 16 might need a third Pfizer dose.

Vaccinations for children as young as 5 just began last month, using special low-dose Pfizer shots. By this week, about 5 million 5- to 11-year-olds had gotten a first dose.

The extra-contagious delta variant is causing nearly all COVID-19 infections in the U.S., and in much of the world. It’s not yet clear how vaccines will hold up against the new and markedly different omicron mutant. But there’s strong evidence that boosters offer a jump in protection against delta-caused infections, currently the biggest threat.

Complicating the decision to extend boosters to 16- and 17-year-olds is that the Pfizer shot -- and a similar vaccine made by Moderna -- have been linked to a rare side effect. Called myocarditis, it’s a type of heart inflammation seen mostly in younger men and teen boys.

The FDA said rising COVID-19 cases in the U.S. mean the benefits of boosters greatly outweighed the potential risk from the rare side effect, especially as the coronavirus itself can cause more serious heart inflammation.

Health officials in Israel, which already gives boosters to teens, have said the side effect continues to be rare with third doses.

A U.S. study this week offered additional reassurance. Researchers from children’s hospitals around the country checked medical records and found the rare side effect usually is mild and people recover quickly. The research was published Monday in the journal Circulation.

___

Associated Press reporter Matthew Perrone contributed to this report.

Share:
More In Science
The Space Race In 2022
2021 was an exciting year for space innovations, but 2022 could hold even more in store. Cheddar took a deep dive into the space mission on tap for the year ahead.
U.S. Purchases 600K Doses of New Antibody Treatment Amid Omicron Surge
The United States purchased over 600,000 doses of a monoclonal antibody treatment from Glaxosmithkline and Vir Biotechnology, bringing the total worldwide doses purchased to 1.7 million. This comes as the country attempts to ramp up treatment options as cases of the omicron variant continue to surge. Dr. Asha Shah, Director of Infectious Diseases at Stamford Health joined Cheddar's Opening Bell to discuss.
2021: A Rebound of the Economy and Greenhouse Gas Emissions
As the pandemic slammed the brakes on the nation's economy in 2020, America's greenhouse gas emissions reached their lowest levels in at least three decades. However, as the world, and the economy re-opened, 2021 told a much different story as emissions surged. Biden's flagship 'Build Back Better' act involves billions in spending on electric cars and renewables, in an effort to cut U.S. emissions, experts are still skeptical that the nation will meet the current 2030 target. Andrew Dessler, professor of atmospheric sciences at Texas A&M University, joins Cheddar News.
Experts Debate Throat vs. Nasal Swabs for Omicron Testing
Amid the omicron surge, a new debate has emerged about whether or not throat swabs are more effective than nasal swabs for COVID testing. Dr. William Schaffner, MD, professor of infectious diseases, Vanderbilt Medical Center, sat down with Cheddar's News Wrap to weigh in on the dispute. "Should there be a change? You've got to do the studies, show that in the field [a throat swab] works as well or better than the nasal specimen," he said. "Let's not do it off our hips, as we say."
State of Emergency Declared in Virginia, as Multiple States Face Extreme Winter Weather
Virginia Governor Ralph Northam is declaring a state of emergency after Monday's winter storm left hundreds of drivers stranded on the interstate for more than 24 hours. The snow also knocked out power for many residents, with more than 100,000 outages remaining days later. Michael Wehner, a climate scientist at Lawrence Berkeley national laboratory, discusses recent weather disasters.
Walmart and Kroger Raise At-Home Covid Test Prices
As the need for COVID-19 testing increases, so does the price of the tests themselves. An agreement with The White House and several major companies to sell the tests at a lower cost has now expired, sending prices up as retailers struggle to keep kits on shelves. Dr. Thomas McGinn, executive VP of physician enterprise at Common Spirit Health, joins Cheddar News to discuss.
Emission Surge Puts U.S. Further Off Track from Climate Targets
A new report shows 2021 saw a surge in U.S. greenhouse gas emissions, indicating that the country remains far off track from meeting President Biden's climate change targets. Biden previously pledged to cut the nation's emissions in half by 2030, and now experts warn that immediate action must be taken in order to get the nation back on track. Zeke Hausfather, director of climate and energy at The Breakthrough Institute on U.S. Emissions and Global Temperatures, joins Cheddar News to discuss.
Toyota's Chief Scientist on Importance of Diversifying EV Fleets, Including Hybrid Models
Electric vehicles are quickly becoming an accessible way for consumers to slash emissions as legacy automakers begin to electrify their fleets and world leaders including President Joe Biden push for broad EV adoption. But consumers have concerns about EV range, the availability of charging stations, and more. What if it were both helpful to consumers — and feasible from a climate change standpoint — to keep hybrid models that run on gas on the market? Gill Pratt, CEO of the Toyota Research Institute & Toyota Motor Corporation's Chief Scientist joins Cheddar Climate to discuss his team's research about 'carbon return on investment,' how Toyota is electrifying its fleet, and more.
Major Cold Snap Settles Across Much of the U.S.
It's a painfully cold week across a large portion of the U.S. with more than 185 million Americans experiencing below-freezing temperatures on Monday and 10 million of them dealing with dangerous sub-zero temps.
Load More